Juno licenses gamma secretase inhibitor, related IP

By Jaime De Leon | Dec 6, 2017 | 11:05 PM GMT

Juno Therapeutics Inc. (NASDAQ:JUNO) announced on Wednesday a trio of licensing agreements to advance its multiple myeloma (MM) program combining gamma secretase inhibitors

Read the full 231 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE